PF-Atlas › Clinical Trials › NCT06683612

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

PIPE-791 · Phase 1

Registry ID

NCT06683612

Phase

Phase 1

Status

Completed

Drug / intervention

PIPE-791

Sponsor

Contineum Therapeutics

Start

2024-12-09

Enrollment

Locations

About this trial

This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients. Participants will: * Take a single dose of the study drug * Give many samples of blood and urine * Have multiple PET scans

View NCT06683612 on ClinicalTrials.gov →

Explore related

All PIPE-791 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT06683612 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.